|Mr. Patrick J. Mahaffy MA||Co-Founder, Chief Exec. Officer, Pres and Exec. Director||788.62k||N/A||54|
|Dr. Gillian C. Ivers-Read BSc||Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations||735.17k||N/A||63|
|Mr. Daniel W. Muehl CPA||Sr. VP of Fin. and Principal Financial & Accounting Officer||492.36k||N/A||53|
|Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM||Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance||724.92k||N/A||49|
|Mr. Corwin Dale Hooks||Chief Commercial Officer and Sr. VP||585.27k||N/A||50|
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Clovis Oncology, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 6. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 9; Compensation: 5.